Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK

EU Horizon 2020 Research and Innovation programme, Medical Research Council and Foreign Commonwealth and Development Office Concordat agreement, European and Developing Countries Clinical Trials Partnership, National Institute for Health Research Oxford Biomedical Research Centre, and IAVI.

Authors

Abigail Platt
Tomáš Hanke (ORCID: https://orcid.org/0000-0002-6076-9546)
Marion Watson (ORCID: https://orcid.org/0000-0001-8570-2113)
Nicholas Byard
Oliver Conway
Paola Cicconi (ORCID: https://orcid.org/0000-0001-6347-966X)
Ian Poulton (ORCID: https://orcid.org/0000-0002-6603-8461)
Nicola Borthwick
Michael Luciw
Daniel Jenkin (ORCID: https://orcid.org/0000-0003-3088-310X)
Colin W. Larkworthy
Peter Hayes (ORCID: https://orcid.org/0000-0002-1251-934X)
Alison Crook (ORCID: https://orcid.org/0000-0001-9724-8309)
Molly Glaze (ORCID: https://orcid.org/0000-0001-6529-6189)
Natalia Fernández (ORCID: https://orcid.org/0000-0002-4213-079X)
Merin Thomas (ORCID: https://orcid.org/0000-0003-3482-7199)
Andrea Baines (ORCID: https://orcid.org/0000-0002-9372-415X)
Belkis M. Akis Yildirim
Edmund G. Wee
Megan Baker
Jack Quaddy

Institutions

Jenner Institute (GB)
Imperial College London (GB)

Publication Details

Journal: The Lancet Microbe
Published: 2024-11-26
DOI: https://doi.org/10.1016/j.lanmic.2024.100956
Citations: 7
Primary Topic: HIV Research and Treatment
Type: article
Field-Weighted Citation Impact: 2.06

Funders

United States Agency for International Development
International AIDS Vaccine Initiative
National Institute for Health and Care Research
European Commission
Foreign, Commonwealth and Development Office
Medical Research Council
Horizon 2020
NIHR Oxford Biomedical Research Centre
European and Developing Countries Clinical Trials Partnership

Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK

Abigail Platt, Tomáš Hanke, Marion Watson, Nicholas Byard, Oliver Conway, Paola Cicconi, Ian Poulton, Nicola Borthwick, Michael Luciw, Daniel Jenkin, Colin W. Larkworthy, Peter Hayes, Alison Crook, Molly Glaze, Natalia Fernández, Merin Thomas, Andrea Baines, Belkis M. Akis Yildirim, Edmund G. Wee, Megan Baker, Jack Quaddy

November 26, 2024article en

7 citations

Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK

Authors

Institutions

Publication Details

Funders

Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK

Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.